A variety of data, from both animal and human behavioral investigations and receptor studies, implicates the sigma receptor in the actions of certain psychotomimetic drugs (benzomorphan opiates, PCP) and also certain novel antipsychotic drugs under development (rimcazole, remoxipride). Di-o-tolyl-guanidine (DTG), developed by consultants to CNS Research, appears to be one of the most selective and potent ligands for the sigma receptor and shows activity like that of the sigma receptor-binding antipsychotic drugs in bioassays. In order to characterize a series of DTG analogs for their drug development potential, CNS Research plans in Phase I of this project to: 1) examine the specificity of these compounds for the sigma receptor by a) additional receptor binding studies and b) synthesizing and testing radiolabeled versions of a few very high affinity analogs; 2) test the antagonist/agonist activity of the analogs in bioassays; and 3) determine the ability of the radiolabeled analogs to cross the blood- brain barrier. Based on these results, a lead compound(s) will be selected for further pharmaceutical development. In Phase II of this project, the extensive metabolic and toxicological testing required for an IND application will be performed on the best compound, and clinical trials arranged.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Small Business Innovation Research Grants (SBIR) - Phase I (R43)
Project #
1R43MH045735-01
Application #
3503199
Study Section
Mental Health Small Business Research Review Committee (MHSB)
Project Start
1989-08-01
Project End
1990-01-31
Budget Start
1989-08-01
Budget End
1990-01-31
Support Year
1
Fiscal Year
1989
Total Cost
Indirect Cost
Name
Cambridge Neuroscience
Department
Type
DUNS #
City
Norwood
State
MA
Country
United States
Zip Code
02062